Comprehensive analysis of PD-L1 expression in glioblastoma multiforme
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 3558 views | HTML 4138 views | ?
Dieter Henrik Heiland1,4, Gerrit Haaker1,4, Daniel Delev1,4, Bianca Mercas1,4, Waseem Masalha1,4, Sabrina Heynckes1,4, Annette Gäbelein1,4, Dietmar Pfeifer2,4, Maria Stella Carro1,4, Astrid Weyerbrock1,4, Marco Prinz3,4,5 and Oliver Schnell1,4
1Department of Neurosurgery, Medical Center - University of Freiburg, Baden-Württemberg, Germany
2Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center - University of Freiburg, Baden-Württemberg, Germany
3Institute of Neuropathology, Medical Center - University of Freiburg, Baden-Württemberg, Germany
4Faculty of Medicine, University of Freiburg, Baden-Württemberg, Germany
5BIOSS Centre for Biological Signalling Studies, University of Freiburg, Baden-Württemberg, Germany
Dieter Henrik Heiland, email: [email protected]
Keywords: glioblastoma multiforme, PD-L1, WGCNA, integrative analysis, immunotherapy
Received: September 09, 2016 Accepted: January 10, 2017 Published: February 02, 2017
Glioblastoma multiforme are highly malignant brain tumours with frequent genetic and epigenetic alterations. The poor clinical outcome of these tumours necessitates the development of new treatment options. Immunotherapies for glioblastoma multiforme including PD1/PD-L1 inhibition are currently tested in ongoing clinical trials. The purpose of this study was to investigate the molecular background of PD-L1 expression in glioblastoma multiforme and to find associated pathway activation and genetic alterations. We show that PD-L1 is up-regulated in IDH1/2 wildtype glioblastoma multiforme compared to lower-grade gliomas. In addition, a strong association of PD-L1 with the mesenchymal expression subgroup was observed. Consistent with that, NF1 mutation and corresponding activation of the MAPK pathway was strongly connected to PD-L1 expression. Our findings may explain different response to PD-L1 inhibition of patients in ongoing trials and may help to select patients that may profit of immunotherapy in the future.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.